Abbott Laboratories Income from Continuous Operations 2010-2025 | ABT
Abbott Laboratories annual/quarterly income from continuous operations history and growth rate from 2010 to 2025. Income from continuous operations can be defined as a company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change
- Abbott Laboratories income from continuous operations for the quarter ending June 30, 2025 was $1.779B, a 36.64% increase year-over-year.
- Abbott Laboratories income from continuous operations for the twelve months ending June 30, 2025 was $13.979B, a 151.56% increase year-over-year.
- Abbott Laboratories annual income from continuous operations for 2024 was $13.402B, a 134.18% increase from 2023.
- Abbott Laboratories annual income from continuous operations for 2023 was $5.723B, a 17.45% decline from 2022.
- Abbott Laboratories annual income from continuous operations for 2022 was $6.933B, a 1.95% decline from 2021.
| Abbott Laboratories Annual Income from Continuous Operations (Millions of US $) |
|
|---|---|
| 2024 | $13,402 |
| 2023 | $5,723 |
| 2022 | $6,933 |
| 2021 | $7,071 |
| 2020 | $4,471 |
| 2019 | $3,687 |
| 2018 | $2,334 |
| 2017 | $353 |
| 2016 | $1,063 |
| 2015 | $2,606 |
| 2014 | $1,721 |
| 2013 | $1,988 |
| 2012 | $237 |
| 2011 | $1,126 |
| 2010 | $4,626 |
| 2009 | $5,746 |
| Abbott Laboratories Quarterly Income from Continuous Operations (Millions of US $) |
|
|---|---|
| 2025-06-30 | $1,779 |
| 2025-03-31 | $1,325 |
| 2024-12-31 | $9,229 |
| 2024-09-30 | $1,646 |
| 2024-06-30 | $1,302 |
| 2024-03-31 | $1,225 |
| 2023-12-31 | $1,594 |
| 2023-09-30 | $1,436 |
| 2023-06-30 | $1,375 |
| 2023-03-31 | $1,318 |
| 2022-12-31 | $1,033 |
| 2022-09-30 | $1,435 |
| 2022-06-30 | $2,018 |
| 2022-03-31 | $2,447 |
| 2021-12-31 | $1,989 |
| 2021-09-30 | $2,100 |
| 2021-06-30 | $1,189 |
| 2021-03-31 | $1,793 |
| 2020-12-31 | $2,158 |
| 2020-09-30 | $1,232 |
| 2020-06-30 | $537 |
| 2020-03-31 | $544 |
| 2019-12-31 | $1,049 |
| 2019-09-30 | $960 |
| 2019-06-30 | $1,006 |
| 2019-03-31 | $672 |
| 2018-12-31 | $655 |
| 2018-09-30 | $552 |
| 2018-06-30 | $718 |
| 2018-03-31 | $409 |
| 2017-12-31 | $-864 |
| 2017-09-30 | $561 |
| 2017-06-30 | $270 |
| 2017-03-31 | $386 |
| 2016-12-31 | $765 |
| 2016-09-30 | $-357 |
| 2016-06-30 | $599 |
| 2016-03-31 | $56 |
| 2015-12-31 | $695 |
| 2015-09-30 | $596 |
| 2015-06-30 | $786 |
| 2015-03-31 | $529 |
| 2014-12-31 | $634 |
| 2014-09-30 | $438 |
| 2014-06-30 | $425 |
| 2014-03-31 | $224 |
| 2013-12-31 | $324 |
| 2013-09-30 | $644 |
| 2013-06-30 | $476 |
| 2013-03-31 | $544 |
| 2012-12-31 | $-864 |
| 2012-09-30 | $339 |
| 2012-06-30 | $411 |
| 2012-03-31 | $351 |
| 2011-12-31 | $1,619 |
| 2011-09-30 | $303 |
| 2011-06-30 | $1,943 |
| 2011-03-31 | $864 |
| 2010-12-31 | $1,441 |
| 2010-09-30 | $891 |
| 2010-06-30 | $1,292 |
| 2010-03-31 | $1,003 |
| 2009-12-31 | $1,539 |
| 2009-09-30 | $1,480 |
| 2009-06-30 | $1,288 |
| 2009-03-31 | $1,439 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $229.514B | $41.950B |
| Abbott Labs discovers, develops, manufactures & sells a diversified line of health care products. Established Pharmaceuticals Division includes branded generics business in the emerging markets. Medical Devices unit includes the diabetes care, vision care & vascular businesses. Diagnostics unit manufactures and markets diagnostic systems and tests in four business lines core laboratory, molecular, point of care and rapid diagnostics. Nutrition unit includes a broad line of pediatric and adult nutritional products. Abbott acquired CFR Pharmaceuticals, Tendyne Holdings, Inc., St. Jude Medical and Alere Inc. On the other hand, Abbott sold its developed markets branded generics pharmaceuticals business to Mylan. Abbott retained the branded generics pharmaceuticals business in emerging markets. Abbott sold its animal health business to Zoetis Inc and divested its vision care business, Medical Optics, to Johnson & Johnson. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Boston Scientific (BSX) | United States | $155.747B | 37.14 |
| Stryker (SYK) | United States | $149.436B | 30.42 |
| EssilorLuxottica (ESLOY) | France | $144.168B | 0.00 |
| Medtronic (MDT) | Ireland | $117.977B | 16.64 |
| Lonza Group Ag (LZAGY) | Switzerland | $49.715B | 0.00 |
| Haleon (HLN) | United Kingdom | $43.412B | 24.82 |
| ResMed (RMD) | United States | $41.845B | 29.93 |
| GE HealthCare Technologies (GEHC) | United States | $34.055B | 16.01 |
| Agilent Technologies (A) | United States | $33.846B | 22.07 |
| Koninklijke Philips (PHG) | Netherlands | $26.577B | 17.58 |
| Terumo (TRUMY) | Japan | $26.206B | 31.05 |
| Insulet (PODD) | United States | $23.159B | 77.59 |
| Zimmer Biomet Holdings (ZBH) | United States | $21.260B | 13.53 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $16.271B | 0.00 |
| Baxter (BAX) | United States | $12.615B | 9.75 |
| Sunny Optical Technology (SNPTF) | China | $10.800B | 0.00 |
| Demant (WILYY) | Denmark | $8.121B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $8.048B | 29.56 |
| Lantheus Holdings (LNTH) | United States | $3.819B | 10.32 |
| Envista Holdings (NVST) | United States | $3.510B | 24.56 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| Perrigo (PRGO) | Ireland | $3.272B | 8.17 |
| Prestige Consumer Healthcare (PBH) | United States | $3.231B | 14.34 |
| ICU Medical (ICUI) | United States | $3.106B | 21.15 |
| Haemonetics (HAE) | United States | $2.661B | 11.88 |
| LeMaitre Vascular (LMAT) | United States | $2.209B | 47.38 |
| Acuren (TIC) | United States | $2.126B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $2.005B | 0.00 |
| AtriCure (ATRC) | United States | $1.881B | 0.00 |
| QuidelOrtho (QDEL) | United States | $1.877B | 11.82 |
| Green Thumb Industries (GTBIF) | United States | $1.869B | 80.25 |
| Tilray Brands (TLRY) | Canada | $1.530B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $1.295B | 16.55 |
| AdaptHealth (AHCO) | United States | $1.249B | 17.75 |
| BioLife Solutions (BLFS) | United States | $1.229B | 2565.00 |
| Neogen (NEOG) | United States | $1.216B | 19.31 |
| InMode (INMD) | Israel | $0.921B | 8.52 |
| Kestra Medical Technologies (KMTS) | United States | $0.910B | 0.00 |
| Valneva SE (VALN) | France | $0.802B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.648B | 0.00 |
| SNDL (SNDL) | Canada | $0.631B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.613B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.593B | 0.00 |
| ZimVie (ZIMV) | United States | $0.535B | 20.61 |
| Surmodics (SRDX) | United States | $0.505B | 0.00 |
| Evolus (EOLS) | United States | $0.481B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.473B | 16.29 |
| CeriBell (CBLL) | United States | $0.419B | 0.00 |
| Owens & Minor (OMI) | United States | $0.396B | 3.51 |
| Sanuwave Health (SNWV) | United States | $0.366B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.345B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.331B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.317B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.302B | 0.00 |
| Omeros (OMER) | United States | $0.296B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.295B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.293B | 0.00 |
| Brainsway (BWAY) | Israel | $0.290B | 59.08 |
| High Tide (HITI) | Canada | $0.283B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.275B | 20.85 |
| TriSalus Life Sciences (TLSI) | United States | $0.246B | 0.00 |
| Cerus (CERS) | United States | $0.245B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.243B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.230B | 0.00 |
| Organigram Global (OGI) | Canada | $0.219B | 0.00 |
| Quanterix (QTRX) | United States | $0.217B | 0.00 |
| Exagen (XGN) | United States | $0.217B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.193B | 16.13 |
| FitLife Brands (FTLF) | United States | $0.171B | 21.05 |
| Biote (BTMD) | United States | $0.160B | 5.30 |
| Jushi Holdings (JUSHF) | United States | $0.142B | 0.00 |
| Jin Medical (ZJYL) | China | $0.133B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.113B | 0.00 |
| MacroGenics (MGNX) | United States | $0.104B | 0.00 |
| Fonar (FONR) | United States | $0.095B | 12.31 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.089B | 0.00 |
| Apyx Medical (APYX) | United States | $0.078B | 0.00 |
| Agape ATP (ATPC) | $0.066B | 0.00 | |
| Safety Shot (SHOT) | United States | $0.066B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.057B | 0.00 |
| ImmuCell (ICCC) | United States | $0.055B | 32.03 |
| Veru (VERU) | United States | $0.051B | 0.00 |
| Zynex (ZYXI) | United States | $0.051B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.045B | 0.00 |
| Nephros (NEPH) | United States | $0.044B | 34.92 |
| Modular Medical (MODD) | United States | $0.042B | 0.00 |
| United-Guardian (UG) | United States | $0.037B | 14.36 |
| Trinity Biotech (TRIB) | Ireland | $0.028B | 0.00 |
| Senestech (SNES) | United States | $0.023B | 0.00 |
| INLIF (INLF) | $0.018B | 0.00 | |
| Allurion Technologies (ALUR) | United States | $0.017B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.015B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.013B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.012B | 0.00 |
| Flora Growth (FLGC) | United States | $0.012B | 0.00 |
| Sharps Technology (STSS) | United States | $0.011B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.007B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.004B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| InterCure (INCR) | Israel | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |